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Abstract 
 
In the last 15 years two major advances in the role of complement in the kidney transplant have come 
about. The first is that ischaemia reperfusion injury and its profound effect on transplant outcome is 
dependent on the terminal product of complement activation, C5b-9. The second key observation 
relates to the function of the small biologically active fragments C3a and C5a released by complement 
activation in increasing antigen presentation and priming the T cell response that results in transplant 
rejection. In both cases local synthesis of C3 principally by the renal tubule cells plays an essential role 
that overshadows the role of the circulating pool of C3 generated largely by hepatocyte synthesis. 
More recent efforts have investigated the molecules expressed renal tissue that can trigger 
complement activation. These have revealed a prominent effect of collectin-11, a soluble C-type lectin 
that is expressed in renal tissue and aligns with its major ligand L-fucose at sites of complement 
activation following ischaemic stress. Biochemical studies have shown that interaction between CL-11 
and L-fucose results in complement activation by the lectin complement pathway, precisely targeting 
the innate immune response to the ischaemic tubule surface. Therapeutic approaches to reduce 
inflammatory and immune stimulation in ischaemic kidney have so far targeted C3 or its activation 
products and several are in clinical trials. The finding that lectin-fucose interaction is an important 
trigger of lectin pathway complement activation within the donor organ opens up further therapeutic 
targets where intervention could protect the donor kidney against complement. 
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Complement is a major effector system which is comprised of numerous fluid-phase and membrane-
bound protein receptors that interact rapidly and efficiently to clear invading pathogens. In this 
capacity, it is one of the main defence mechanism of the innate immune system. This paradigm has 
shifted significantly in the last decade or so, as complement is now known to interact closely with and 
indeed help direct alloimmune responses to solid organ transplants: not only does complement 
contribute to the damage associated with ischaemia reperfusion injury but it is also critical in both T 
cell-mediated and antibody-mediated rejection (Sacks and Zhou, 2012). Activation of the complement 
system is well-recognised as a key effector that mediates antibody-mediated rejection, as evidenced 
by the characteristics of donor-specific antibodies against MHC molecules (Loupy, et al., 2013). In solid 
organ transplantation, complement can directly damage the organ by coordinating the innate immune 
response associated with tissue hypoxia and oxidative stress, and can stimulate and modulate the 
specific anti-donor immune response. Additionally, recent evidence points to complement activation 
as a significant factor in the progression of chronic kidney disease (Fearn and Sheerin, 2015). From a 
clinical perspective, therapies that target effector functions of the complement system could be 
tailored more specifically if the key initiators of complement activation can be identified. This provides 
scope for guiding the development of intervention therapies that do not interfere with the anti-
microbial effector functions of complement, such as opsonisation, cell lysis and the recruitment of 
inflammatory cells such as neutrophils (Ricklin, et al., 2010). In this article, we shall focus on current 
observations relating to the role of complement in post-ischaemic injury and allograft rejection, 
emphasising new concepts surrounding the emerging contribution of the lectin pathway of 
complement activation to organ injury, and provide insights into potential new endogenous ligands 
that may serve as useful targets for the design of therapies that aim to prevent injury and extend graft 
survival. 
 
Complement activation and effector mechanisms 
 
Activation of the complement cascade is triggered by three main pathways, i.e. the classical, lectin 
and alternative pathways (Walport, 2001). All three pathways converge at the formation of the pivotal 
complement component C3, which is subsequently cleaved leading to the formation of C5 convertase 
and the eventual recruitment of terminal complement components to form the terminal complement 
complex (C5b-9). Under normal physiological conditions, the activation of complement is tightly 
controlled by both surface-bound and soluble proteins. These protective mechanisms rely on 
enhancing the degradation of a variety of convertases thereby preventing the formation of MAC. 
Under inflammatory conditions, these protective mechanisms are overcome, which can happen 
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during solid organ transplantation, leading to uncontrolled complement-mediated injury and rejection 
(Yamanaka, et al., 2016). In the kidney and other solid organs, ischaemia-reperfusion (I/R) injury is an 
inevitable consequence of transplantation and post-ischaemic renal dysfunction is strongly dependent 
on the local conversion of C3 into its activated form (Zhou, et al., 2000). Thus, it has been established 
that renal tubule cells are not only capable of producing complement proteins (Peake, et al., 1999) 
but also that kidney-derived C3 is a mediator of localised injury and cell death (Farrar, et al., 2006) and 
provides a stimulus to T cell-mediated renal allograft rejection in both mice (Pratt, et al., 2002) and 
humans (Tang, et al., 1999). Downstream of C3 cleavage, C3a and C5a interact with their respective 
receptors on donor parenchymal cells and infiltrating leucocytes (Peng, et al., 2012) to mediate 
reperfusion injury. Engagement of C5aR on dendritic cells and T cells modulates the 
activation/function of these cells and consequently up-regulates the allospecific T cell 
responses, leading to allograft rejection (Li, et al., 2010). The finding that renal I/R injury led to 
parenchymal formation of C5b-9, suggested a contribution of the alternative pathway (Thurman, et 
al., 2003). This observation implied that classical or lectin pathway is needed to trigger the alternative 
pathway but recent findings indicate the lectin pathway is the principal initiator of complement 
activation and consequent tissue injury within the kidney (Farrar, et al., 2012). 
 
The Lectin Pathway 
 
The lectin pathway (LP) of complement activation is initiated when one of a number of well-
characterized molecules known as pattern recognition receptors (PRRs) binds to pathogen-associated 
molecular patterns (PAMPs) that are displayed on the surface of invading microorganisms, or bind 
damage-associated molecular patterns (DAMPs) on endogenous ligands during inflammation 
(Genster, et al., 2014). Currently described LP activation molecules include the collagen-containing 
soluble C-type lectins (collectins), such as kidney collectin-11 (CL-K1) (Selman and Hansen, 2012), 
mannose-binding lectin (MBL) (Thiel, 2007) and surfactant proteins SP-A and SP-D (Waters, et al., 
2009). Ficolins constitute another subset of LP activating molecules that consist of an N-terminal 
collagen-like domain and a terminal fibrinogen-like domain (Endo, et al., 2011). Collectins circulate as 
complexes with MBL-associated serine proteases (MASPs), of which there are three, named MASP-1, 
MASP-2, and MASP-3 (Dahl, et al., 2001, Thiel, et al., 1997) . Complement activation is initiated when 
these pre-formed complexes of collectins and MASPs bind to pathogens or endogenous ligands 
(Wallis, 2007). 
 
Lectin Pathway in organ injury 
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MASP-2 activity is an absolute requirement for activation of the LP, with the traditional view being 
that MASP-2-mediated cleavage of C4 and C2 generates the classical C3 convertase C4b2a. However, 
a recent study has revealed a C4-independent bypass lectin activation pathway (Schwaeble, et al., 
2011). In models both of cardiac and intestinal I/R injury, MASP-2 was found to be essential to mediate 
injury, even in the absence of C4. This suggested that the lectin pathway can cleave C3 without using 
the classical pathway components C4 and C2. In a further study, with a renal isograft model in wild 
type and MASP-2-deficient mice, absence of the serine protease was shown to reduce kidney injury; 
again, the protective effect was shown to be independent of C4, highlighting the importance of the 
C4-bypass route triggered by the LP in mediating tissue injury (Asgari, et al., 2014). Moreover, the 
findings help to account for other observations in the kidney, where absence of C4 in both native 
ischaemia (Zhou, et al., 2000) and renal allograft rejection (Lin, et al., 2006), failed to give protection 
from injury. Hence, in the heart as well as the kidney, there appears to be present a novel mechanism 
of LP activation. These findings raise questions as to what may be the initiating trigger of the LP of 
complement activation during ischaemia which is associated with whole organ transplantation. 
 
Mannan binding lectin (MBL) in reperfusion injury 
 
A role for MBL in renal and cardiac IR injury has been suggested. A study performed in mice and 
humans found that deposits of Mbl-1 and Mbl-2 co-localized with complement C3 (de Vries, et al., 
2004). In a further study, mice deficient for both MBL-A and MBL-C displayed blunted ischaemic injury 
that was reversed following administration of recombinant MBL (Moller-Kristensen, et al., 2005). In a 
separate study, serum-derived MBL was found deposited with C3b on highly glycosylated zinc 
metalloproteases (meprins α and β) within ischaemic mouse kidney (Hirano et al, 2012). Furthermore, 
in a rodent model of cardiac ischaemia, both MBL and C3 deposition were found following the 
induction of ischaemia (Collard, et al., 2000). Though these studies suggest that MBL mediated the 
observed pattern of injury, a contribution of the classical pathway as a mediator of injury could not be 
ruled out. As well as binding carbohydrates on microorganisms, MBL is known to bind to carbohydrate 
moieties on certain immunoglobulin subclasses, namely IgA (Roos, et al., 2006) and IgM (McMullen, 
et al., 2006). Further investigation in ischaemic heart unveiled a pathophysiology that was dependent 
upon the interaction of both naturally-occurring IgM and mannose-binding lectin (Busche, et al., 2009) 
but with no involvement of the classical pathway (Walsh, et al., 2005). Further evidence for LP 
involvement in the presence of bound immunoglobulin derives from a model of ischaemic skeletal 
injury, in which naturally-occurring self-reactive IgM was identified to play a part in the injury (Zhang, 
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et al., 2004). This IgM has since been found to bind the self-antigen non-muscle myosin heavy chain 
type II (Zhang, et al., 2006) and the actin cytoskeleton (Shi, et al., 2009). 
 
In human renal allograft rejection however, the evidence for MBL participation has been somewhat 
conflicting. With the prediction that higher MBL levels may be associated with increased complement-
mediated allograft injury, a study showed that higher pre-transplant levels of MBL were found to be 
associated with more severe kidney rejection (Berger, et al., 2005). In a second study in which patients 
with type I diabetes and renal failure received a simultaneous pancreas and kidney transplant, patients 
with gene polymorphisms associated with lower levels of MBL had improved survival rates (Berger, et 
al., 2007). A number of studies have demonstrated contrasting findings, however. In a recent study, a 
large number of donor-recipients pairs were profiled for genes including MBL-2 and MASP-2 and it 
was clearly determined that the MBL-2/MASP-2 genotypes had no association with graft outcome 
(Damman, et al., 2012). Whereas that study showed no correlation, other groups have observed an 
inverse correlation between MBL and graft outcome: in non-HLA-sensitized patients, a low serum level 
of MBL was found to be associated with a decrease in the 5-year survival rate of renal allografts (Bay, 
et al., 2013). It was speculated that the difference between outcomes observed in different centres 
could be explained by difference in laboratory antibodies and assays employed to generate data sets 
(Damman and Seelen, 2013). In a more recent study, low pre-transplant levels of MBL in renal 
transplant recipients correlated with increased severity of renal inflammation and an increase in 
tubular cell necrosis (Ibernon, et al., 2014). Similarly, in a Swiss study, it was determined that MBL-2 
polymorphisms resulted in low serum MBL levels which was associated with poor graft outcome 
(Golshayan, et al., 2016). 
 
Ficolins in reperfusion injury 
 
In humans three ficolins are described (Genster, et al., 2014), namely ficolin-1, ficolin-2 and ficolin-3. 
Only a limited number of studies have examined the role of ficolins in human allograft rejection. In a 
study investigating lectin gene profiles of over 1200 donor and recipient pairs, analysis of ficolin-2 
gene haplotypes showed no association with allograft survival (Damman, et al., 2012). However, other 
reports have documented conflicting findings. For example, a common functional polymorphism in 
the ficolin-2 gene was found to be associated with a lower incidence of renal transplant rejection. The 
authors concluded that the polymorphism led to more efficient phagocytosis of damaged tissue with 
concurrent dampening of alloimmune responses (Eikmans, et al., 2012). High pre-transplant levels of 
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the most abundant ficolin in serum, ficolin-3, shows a strong association with poor allograft survival 
after kidney transplantation (Bay, et al., 2013, Smedbraten, et al., 2015). 
 
What triggers MASP-2-dependent complement-mediated reperfusion injury? 
 
It has been conclusively demonstrated in rodent models of reperfusion injury both for native and 
transplanted organs that MASP-2 is a key mediator of pathology (Asgari, et al., 2014, Farrar, et al., 
2006, Schwaeble, et al., 2011). This raises the question as to which collectin preferentially triggers 
MASP-2 to initiate complement activation. As discussed above, there are several candidate lectins that 
could interact with MASP-2 at the site of tissue injury. However, in the case of MBL, synthesis primarily 
takes place in hepatocytes and it exists in the serum as oligomers with large molecular mass, which 
could limit the interaction between MBL and target structures in the extravascular compartment 
following I/R insult. This therefore raises the possibility of a role for the recently described PRR known 
as collectin-11 (CL-11), which is reported to be locally expressed within a number of organs. 
 
Collectin-11 
 
Collectin-11 (CL-11; also known as Collectin Kidney-1, CL-K1) is a recently described component of the 
innate immune system (Keshi, et al., 2006). Like MBL, the structure of CL-11 consists of a globular head 
that forms oligomers of 100 to 200 kDa (Selman and Hansen, 2012) and associates with MASPs via 
binding motifs within its collagenous portion (Ma, et al., 2013). It is synthesized by most tissues, 
including the liver, brain and heart, with significant production assigned to the kidney (Farrar, et al., 
2016, Keshi, et al., 2006, Selman and Hansen, 2012). CL-11 is known to have significant interaction 
with bacteria (Hansen, et al., 2010, Ma, et al., 2013), indicating a significant role in host defence 
against pathogens and the carbohydrate recognition domain is known to bind a number of moieties, 
showing a preference for L-fucose (Keshi, et al., 2006). Interestingly, it has recently been 
demonstrated that CL-11 displays strong binding to nucleic acids and hence may have a role in the 
clearance of apoptotic cells following inflammatory damage (Henriksen, et al., 2013). Indeed, CL-11 is 
likely to be a significant component of inflammatory responses, since a recent study conducted in over 
500 patients with disseminated intravascular coagulation (DIC) - a disorder associated with immune 
system activation - found that circulating serum levels of CL-11 were approximately two-fold above 
the normal range (Takahashi, et al., 2014). 
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Collectin-11 as a trigger of renal epithelial inflammation 
 
The kidney tubule cell appears to be the main source of CL-11 in normal renal tissue and the level of 
expression is markedly elevated following renal I/R stress (Farrar, et al., 2016). In this context, CL-11 
and the complement activation product C3d were found co-localised along the renal tubule 
basolateral surface in the hypoxia-sensitive zone of inner renal cortex, in close association with L-
fucose. L-fucose is a preferred ligand for CL-11 in man and mouse (Farrar, et al., 2016, Selman and 
Hansen, 2012) and a component of many glycans that are produced by renal epithelial cells and are 
expressed at the cell surface, making it very likely that lectin pathway involvement in this injury is 
triggered by CL-11 (Figure 1). 
 
This is further supported by the finding that mice with gene deleted CL-11 were found to be resistant 
to post-ischaemic renal failure and associated complement-mediated damage. The mechanism 
appears to involve the expression of an abnormal pattern of fucosylated cell surface ligand following 
hypoxic insult, which induces CL-11 attachment followed MASP-2-mediated complement activation, 
based on ex vivo analysis in renal tubule cells (Farrar, et al., 2016). Experiments with transplanted 
kidney confirmed the importance of locally derived CL-11 in injury induced by cold ischaemic insult, 
suggesting that it should be possible to engineer protection by pharmacologically blocking the 
collectin-ligand interaction site on the donor organ. The broader implication of these findings in other 
inflammatory conditions and tissue sites remains to be determined. 
 
Concluding remarks 
 
Clinical trials will tell if complement is a viable therapeutic target for improving the outcomes of renal 
transplantation, and several relevant trials are currently in progress. One of the key questions 
concerns where to inhibit complement: C3 or C5. Recent studies have provided a clearer signal that 
the lectin pathway is involved, thereby identifying an additional and more proximal intervention site 
in the early pathogenic response to ischaemic stress. This is an ever pressing question for renal 
transplantation, given the need to use donor organs that have a substantial risk of ischaemic injury. 
Precision treatment targeted to the appropriate complement subcomponent and tissue compartment 
will depend on clear understanding of the molecular and cellular mechanisms in each type of 
pathology. This seems increasingly to implicate a role for the lectin pathway and related tissue ligands. 
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